Kairos signs IIR agreement with Bayer
Kairos Pharma entered into an investigator-initiated research agreement with Bayer to conduct a clinical study, eliminating immediate revenue impact from the deal. The non-binding nature of the agreement precludes triggering of material financial disclosures under certain SEC rul
View filing at SEC.gov →